Free Trial
NASDAQ:ACET

Adicet Bio (ACET) Stock Price, News & Analysis

$1.53
-0.10 (-6.13%)
(As of 05/23/2024 ET)
Today's Range
$1.53
$1.64
50-Day Range
$1.33
$2.40
52-Week Range
$1.10
$6.15
Volume
511,098 shs
Average Volume
1.58 million shs
Market Capitalization
$125.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.83

Adicet Bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
738.8% Upside
$12.83 Price Target
Short Interest
Bearish
9.35% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.53mentions of Adicet Bio in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.36) to ($1.81) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.90 out of 5 stars

Medical Sector

597th out of 916 stocks

Pharmaceutical Preparations Industry

271st out of 407 stocks

ACET stock logo

About Adicet Bio Stock (NASDAQ:ACET)

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

ACET Stock Price History

ACET Stock News Headlines

JMP Securities Sticks to Their Hold Rating for Adicet Bio (ACET)
Adicet Bio (NASDAQ:ACET) Upgraded by StockNews.com to Sell
Adicet Bio (NASDAQ:ACET) Rating Reiterated by Wedbush
Adicet Bio, Inc Q1 Loss Declines
Adicet Bio (NASDAQ: ACET)
Adicet Bio Inc.
ACET Adicet Bio, Inc.
See More Headlines
Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
5/23/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Current Symbol
NASDAQ:ACET
CUSIP
00444610
CIK
2034
Fax
N/A
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.83
High Stock Price Target
$27.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+738.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-142,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$24.99 million
Book Value
$3.15 per share

Miscellaneous

Free Float
66,479,000
Market Cap
$125.73 million
Optionable
Optionable
Beta
1.94
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Chen Schor BAMr. Chen Schor BA (Age 52)
    CPA, M.B.A., CEO, President & Director
    Comp: $871.97k
  • Dr. Aya Jakobovits Ph.D. (Age 69)
    Founder & Independent Director
    Comp: $45k
  • Mr. Brian Nicholas Harvey (Age 63)
    Chief Financial Officer
    Comp: $594.94k
  • Dr. Donald Healey Ph.D. (Age 62)
    Chief Technology Officer
    Comp: $606.34k
  • Dr. Blake Aftab Ph.D. (Age 43)
    Senior VP & Chief Scientific Officer
    Comp: $675.04k
  • Ms. Amy Locke
    Chief Human Resource Officer
  • Dr. Francesco Galimi M.D. (Age 56)
    Ph.D., Chief Medical Officer & Senior VP
    Comp: $680.37k
  • Dr. Nancy L. Boman M.D.
    Ph.D., Senior VP & Chief Regulatory Officer

ACET Stock Analysis - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACET shares.
View ACET analyst ratings
or view top-rated stocks.

What is Adicet Bio's stock price target for 2024?

8 analysts have issued 12-month price objectives for Adicet Bio's stock. Their ACET share price targets range from $5.00 to $27.00. On average, they expect the company's stock price to reach $12.83 in the next year. This suggests a possible upside of 738.8% from the stock's current price.
View analysts price targets for ACET
or view top-rated stocks among Wall Street analysts.

How have ACET shares performed in 2024?

Adicet Bio's stock was trading at $1.89 at the beginning of the year. Since then, ACET stock has decreased by 19.0% and is now trading at $1.53.
View the best growth stocks for 2024 here
.

When is Adicet Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our ACET earnings forecast
.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) released its earnings results on Tuesday, March, 19th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.03.

Is Adicet Bio a good dividend stock?

Adicet Bio (NASDAQ:ACET) pays an annual dividend of $0.04 per share and currently has a dividend yield of 0.00%.
Read our dividend analysis for ACET.

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

Who are Adicet Bio's major shareholders?

Adicet Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.18%), Vanguard Group Inc. (3.81%), Carlyle Group Inc. (3.59%), Blackstone Inc. (1.50%), Johnson & Johnson (0.44%) and Acadian Asset Management LLC (0.43%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Orbimed Advisors Llc and Steve Dubin.
View institutional ownership trends
.

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACET) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners